CORDIS · 115721 · FP7
IABC PROGRAMME iABC Programme
Coordinator: NOVARTIS PHARMA AG (CH)
Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomonas aeruginosa (Pa) is the most frequently isolated pathogen, chronically infecting up to 80% of adult patients. When this occurs patients require lifelong inhaled antibiotic therapy, which although o…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €24.3M toward a total project budget of €58.7M — a funding rate of 41%, with the remainder covered by the consortium partners. The project runs over approximately 6.4 years from 2015-08-01 to 2021-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from CH
see all →- HBP SGA1 — Human Brain Project Specific Grant Agreement 1720270 · H2020 · €89.0M
- HBP SGA2 — Human Brain Project Specific Grant Agreement 2785907 · H2020 · €88.0M
- ATTRACT2 — Breakthrough Innovation Programme for a Pan-European Detection and Imaging Eco-System – Phase-2101004462 · H2020 · €35.0M
- STEMBANCC — Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC)115439 · FP7 · €26.0M
- ULTRA-DD — Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery115766 · FP7 · €21.2M
- EU-AIMS — European Autism Interventions - A Multicentre Study for Developing New Medications115300 · FP7 · €20.5M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
- What is the EU contribution?
- The European Commission contributes €24.3M toward a total project budget of €58.7M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by NOVARTIS PHARMA AG (CH).
- What is the project timeline?
- The project runs from 2015-08-01 to 2021-12-31 — approximately 6.4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115721.